HAVCR2 and melanoma: Treatment with anti-Tim-3 mAbs has been tested in vitro in patients with melanoma and hepatocellular carcinoma as a strategy to overcome T cell exhaustion and potentiate anti-tumor immune response.3 In light of our results, we suggest that the inhibition of Tim-3/Gal-9 pathway may affect the effector function of different leukocyte subsets.